Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by JohnnyUtah16on Mar 16, 2019 9:31am
62 Views
Post# 29495351

RE:Meir Wins in Any Comparison

RE:Meir Wins in Any ComparisonSanspeine, these made up comparisons are completely hypothetical. "Has Medison been in Canada it would have 2 Billion in sales", ummm nope Meir may know the Israel market but not the Canadian. You can't just multiply the sales in one country with a completely different pharma landscape in another by the population of a bigger country and say that will be the new sales multiple. Thats just stupid, did your parents pay your way through school like the hot girl from Full House?

Also why does everyone keep only referencing sales. Who cares about sales if you can't turn those sales into profits. Hey you know who else had a ton of sales Valeant, you know who else, Concordia. How are those companies doing? Sales mean nothing without the ability to turn them into profits and that is something Meir has not proven he can do. Goodman has proven that in spades. Oh and you mention that Paladin did not pay a dividend and implied that Medison is better because supposedly it does. Why would Knight raise money to then turn around and give that same money back in dividends, to then have to raise money again to acquire companies for growth. I'm sure the Paladin shareholders preferred they didn't get dividends and were only rewarded by the measily 9300% share price increase if you held from beginning to end.
Bullboard Posts